IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 224 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $547,267 | -35.2% | 120,279 | +0.2% | 0.17% | -31.9% |
Q2 2023 | $845,001 | +27.0% | 120,029 | +10.2% | 0.25% | +21.0% |
Q1 2023 | $665,248 | +18.8% | 108,879 | +24.2% | 0.21% | +7.7% |
Q4 2022 | $560,084 | +27.3% | 87,650 | +90.6% | 0.20% | +25.0% |
Q3 2022 | $440,000 | -13.4% | 45,977 | 0.0% | 0.16% | -10.9% |
Q2 2022 | $508,000 | -18.8% | 45,977 | +22.3% | 0.18% | -6.4% |
Q1 2022 | $626,000 | -18.3% | 37,600 | -6.2% | 0.19% | -4.1% |
Q4 2021 | $766,000 | -47.2% | 40,100 | -31.8% | 0.20% | -44.4% |
Q3 2021 | $1,450,000 | -4.0% | 58,800 | +1.3% | 0.35% | +3.2% |
Q2 2021 | $1,510,000 | +12.1% | 58,050 | +36.4% | 0.34% | -8.1% |
Q1 2021 | $1,347,000 | -30.2% | 42,550 | +2.3% | 0.37% | -36.0% |
Q4 2020 | $1,930,000 | +68.7% | 41,600 | +19.7% | 0.58% | +33.8% |
Q3 2020 | $1,144,000 | +40.2% | 34,750 | +16.9% | 0.43% | +36.7% |
Q2 2020 | $816,000 | +130.5% | 29,735 | +151.2% | 0.32% | +87.0% |
Q1 2020 | $354,000 | +46.3% | 11,835 | +35.5% | 0.17% | +72.4% |
Q4 2019 | $242,000 | – | 8,735 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 565,890 | $26,257,000 | 9.39% |
Consonance Capital Management LP | 1,710,803 | $79,381,000 | 7.41% |
GREAT POINT PARTNERS LLC | 917,427 | $42,569,000 | 6.91% |
Avoro Capital Advisors LLC | 7,500,000 | $348,000,000 | 5.99% |
Ghost Tree Capital, LLC | 500,000 | $23,200,000 | 5.17% |
FRAZIER MANAGEMENT LLC | 1,312,999 | $60,923,000 | 4.69% |
Perceptive Advisors | 9,166,304 | $425,316,000 | 4.56% |
Ally Bridge Group (NY) LLC | 360,000 | $16,704,000 | 2.86% |
Orbimed Advisors | 6,645,100 | $308,333,000 | 2.70% |
ACUTA CAPITAL PARTNERS, LLC | 164,800 | $7,647,000 | 2.08% |